Cellectis

Albert-ludwigs-universitat Freiburg

Albert-ludwigs-universitaet Freiburg

Marianna Romito

Toni Cathomen

Tatjana Cornu

Claudio Mussolino

Philippe Duchateau

Agnes Gouble

Jamal Alzubi

Sandra Nitsch

Tafadzwa Mlambo

The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.

Sequence specific reagents targeting CCR5 in primary hematopoietic cells

Herein described is a construct for epigenomic modification of genes composed of: (a) a Kr&#xfc;ppel-associated box zinc finger protein or homologous, (b) a DNA region capable of binding to the target gene or homologous, (c) a human DNA methyltransferase DNMT3A or homologous and (d) a murine DNA methyltransferase Dnmt3L or homologous, wherein components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier that can be used to silence genes coding for a protein in leukocytes that avoids the internalization of HI viruses in immune cells.

Construct for epigenetic modification and its use in the silencing of genes

Growing community of inventors

Freiburg, Germany

Marianna Romito